Characterization of three TRAPPC11 variants suggests a critical role for the extreme carboxy terminus of the protein.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 Oct 2019
Historique:
received: 10 04 2019
accepted: 11 09 2019
entrez: 3 10 2019
pubmed: 3 10 2019
medline: 28 10 2020
Statut: epublish

Résumé

TRAPPC11 was identified as a component of the TRAPP III complex that functions in membrane trafficking and autophagy. Variants in TRAPPC11 have been reported to be associated with a broad spectrum of phenotypes but all affected individuals display muscular pathology. Identifying additional variants will further our understanding of the clinical spectrum of phenotypes and will reveal regions of the protein critical for its functions. Here we report three individuals from unrelated families that have bi-allellic TRAPPC11 variants. Subject 1 harbors a compound heterozygous variant (c.1287 + 5G > A and c.3379_3380insT). The former variant results in a partial deletion of the foie gras domain (p.Ala372_Ser429del), while the latter variant results in a frame-shift and extension at the carboxy terminus (p.Asp1127Valfs*47). Subjects 2 and 3 both harbour a homozygous missense variant (c.2938G > A; p.Gly980Arg). Fibroblasts from all three subjects displayed membrane trafficking defects manifested as delayed endoplasmic reticulum (ER)-to-Golgi transport and/or a delay in protein exit from the Golgi. All three individuals also show a defect in glycosylation of an ER-resident glycoprotein. However, only the compound heterozygous subject displayed an autophagic flux defect. Collectively, our characterization of these individuals with bi-allelic TRAPPC11 variants highlights the functional importance of the carboxy-terminal portion of the protein.

Identifiants

pubmed: 31575891
doi: 10.1038/s41598-019-50415-6
pii: 10.1038/s41598-019-50415-6
pmc: PMC6773699
doi:

Substances chimiques

TRAPPC11 protein, human 0
Vesicular Transport Proteins 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14036

Subventions

Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Organisme : CIHR
Pays : Canada

Commentaires et corrections

Type : ErratumIn

Références

PLoS One. 2011;6(8):e23350
pubmed: 21858081
J Clin Neuromuscul Dis. 2017 Sep;19(1):27-30
pubmed: 28827486
Science. 2012 Sep 28;337(6102):1668-72
pubmed: 23019651
J Cell Sci. 2017 Jul 15;130(14):2251-2265
pubmed: 28536105
EMBO J. 2010 Jan 20;29(2):304-14
pubmed: 19942856
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Skelet Muscle. 2018 May 31;8(1):17
pubmed: 29855340
Am J Hum Genet. 2017 Aug 3;101(2):291-299
pubmed: 28777934
Eur J Hum Genet. 2017 Dec;25(12):1364-1376
pubmed: 29158550
J Cell Biol. 2018 Jan 2;217(1):283-298
pubmed: 29109089
Hum Mutat. 2017 Feb;38(2):148-151
pubmed: 27862579
Cell Logist. 2012 Jan 1;2(1):28-42
pubmed: 22645708
Cell Res. 2014 Jan;24(1):69-79
pubmed: 24323045
Cell. 1997 Sep 19;90(6):1137-48
pubmed: 9323141
Skelet Muscle. 2015 Aug 28;5:29
pubmed: 26322222
J Med Genet. 2017 Mar;54(3):176-185
pubmed: 27707803
Sci Rep. 2017 Feb 27;7:43207
pubmed: 28240221
Mol Biol Cell. 2016 Apr 15;27(8):1220-34
pubmed: 26912795
Nat Methods. 2012 Mar 11;9(5):493-8
pubmed: 22406856
Nature. 2010 Jul 1;466(7302):68-76
pubmed: 20562859
Traffic. 2013 Oct;14(10):1091-104
pubmed: 23898804
Cell. 2006 Nov 17;127(4):817-30
pubmed: 17110339
EMBO J. 1998 May 1;17(9):2494-503
pubmed: 9564032
EMBO J. 2016 Feb 1;35(3):281-301
pubmed: 26711178
J Med Genet. 2018 Nov;55(11):753-764
pubmed: 30120216
Ageing Res Rev. 2019 Jan;49:92-103
pubmed: 30502498
Am J Hum Genet. 2013 Jul 11;93(1):181-90
pubmed: 23830518
J Biol Chem. 2005 Aug 12;280(32):29233-41
pubmed: 15951441
Mol Biol Cell. 2000 Dec;11(12):4403-11
pubmed: 11102533
Traffic. 2009 Jun;10(6):724-36
pubmed: 19416478
Traffic. 2019 Jan;20(1):5-26
pubmed: 30152084
Mol Biol Cell. 2011 Jun 15;22(12):2083-93
pubmed: 21525244
J Cell Biol. 2018 Feb 5;217(2):601-617
pubmed: 29273580
Traffic. 2019 May;20(5):325-345
pubmed: 30843302
Case Rep Genet. 2018 Jul 16;2018:8090797
pubmed: 30105108
Mol Biol Cell. 1999 Nov;10(11):3787-99
pubmed: 10564271
Mol Biol Cell. 2012 Mar;23(5):896-909
pubmed: 22219374
Mol Cell. 2001 Feb;7(2):433-42
pubmed: 11239471
Dis Model Mech. 2014 Jul;7(7):823-35
pubmed: 24973751
Methods Enzymol. 2001;329:234-41
pubmed: 11210539
Orphanet J Rare Dis. 2017 Nov 17;12(1):173
pubmed: 29149851
J Cell Biol. 2015 Apr 27;209(2):221-34
pubmed: 25918224

Auteurs

Miroslav P Milev (MP)

Concordia University, Department of Biology, Montreal, Quebec, Canada.

Daniela Stanga (D)

Concordia University, Department of Biology, Montreal, Quebec, Canada.

Anne Schänzer (A)

Institute of Neuropathology, Justus Liebig University Giessen, Giessen, Germany.

Andrés Nascimento (A)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
U705 and U703 Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.

Djenann Saint-Dic (D)

Concordia University, Department of Biology, Montreal, Quebec, Canada.

Carlos Ortez (C)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Daniel Natera-de Benito (D)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Desiré González Barrios (DG)

Servicio de Pediatría, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.

Jaume Colomer (J)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Carmen Badosa (C)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Cristina Jou (C)

U705 and U703 Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Pathology Department and Biobank, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Pia Gallano (P)

U705 and U703 Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Lidia Gonzalez-Quereda (L)

U705 and U703 Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Ana Töpf (A)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.

Katherine Johnson (K)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK.

Volker Straub (V)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.

Andreas Hahn (A)

Department of Child Neurology, Justus Liebig University Giessen, Giessen, Germany. Andreas.Hahn@paediat.med.uni-giessen.de.

Michael Sacher (M)

Concordia University, Department of Biology, Montreal, Quebec, Canada. michael.sacher@concordia.ca.
McGill University, Department of Anatomy and Cell Biology, Montreal, Quebec, Canada. michael.sacher@concordia.ca.

Cecilia Jimenez-Mallebrera (C)

Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain. cjimenezm@fsjd.org.
U705 and U703 Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. cjimenezm@fsjd.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH